Shared on 03 Nov 25
Fair value Increased 3.27%The consensus analyst price target for IDEXX Laboratories has increased by over $22. This reflects growing optimism fueled by expectations of accelerating recurring revenue growth, stronger visit trends, and expanding product adoption in the company's core business lines.
Shared on 20 Oct 25
Fair value Decreased 2.18%Advanced Diagnostics And International Expansion Will Define Future Opportunity
The analyst fair value estimate for IDEXX Laboratories was adjusted downward to $679.92 from $695.09. Analysts highlighted accelerated consumables growth and an expanding installed base, which support long-term growth potential as market conditions normalize.
Shared on 06 Aug 25
Fair value Increased 28%Advanced Diagnostics And International Expansion Will Define Future Opportunity
IDEXX Laboratories’ consensus price target has been sharply raised, reflecting strengthened revenue growth forecasts and a higher future P/E multiple, with fair value increasing from $542.55 to $657.55. What's in the News IDEXX Laboratories raised 2025 earnings guidance, increasing revenue outlook to $4,205–$4,280 million (up $90 million at midpoint) and EPS to $12.40–$12.76 (up $0.40 at midpoint), reflecting strong recurring diagnostics revenue, higher inVue Dx instrument placements, and favorable foreign exchange.
Shared on 07 May 25
Fair value Increased 6.70%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
Shared on 30 Apr 25
Fair value Increased 3.42%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 1.44%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 0.69%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.28%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 1.67%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.23%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 4.22%Early Canine Lymphoma Detection And AI Diagnostics Will Expand Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.